NYU Stern School of Business | Groups
Healthcare Job Boards:
Golgi - Biotech Start-Ups                                                                                                            
Rock Health Job Board - Digital Health
                                                                 
 
Possible health management courses for cross-registration at NYU Wagner: 
 
Healthcare classes previously offered by NYU Stern:  

Health Care Markets

In this course we will apply the tools of economic analysis to study how medical care is produced and financed, in both the private and public sectors. Our emphasis will be on the United States, with a brief treatment of health economics research in other countries and comparisons of health systems in other developed and less developed countries. We will use economics to evaluate why the health care market is different from conventional markets and what economic analysis can tell us about these differences. This will include studying such matters as why health insurance exists, whether hospital competition leads to efficient allocation of resources and production, the role of the physician in treatment choice and the role for government and market interventions in correcting potential inefficiencies. Through the example of the health care sector, we will examine many of the important issues in economics and management, including decision-making under uncertainty, principal-agent theory, moral hazard, and market power.

Topics in Investments - Financial Analysis in Healthcare
In this course students will acquire a framework to evaluate healthcare investment opportunities.  More specifically, students will:
  • Learn the basic structure of the US healthcare system and its history with regard to product regulation and payment.
  • Evaluate science by understanding how to effectively apply an understanding of clinical context, regulatory requirements, and basic statistics.
  • Understand the importance of intellectual property and the impact it has upon healthcare business models.
  • Forecast income statements for various kinds of healthcare business models. Become thoughtful when faced with thinking about product pricing, market forecasting, reimbursement, patent expiration, litigation, competition, and operating expenses.
  • Perform valuation analysis including basic DCF and comparables analysis. Appreciate the strengths and limitations of valuation approaches.
  • Appreciate macroeconomic and industry challenges and be aware of how this may impact healthcare business models in the future.
Pharmaceutical Marketing / Innovation in Pharma & Biotech
Although the pharmaceutical industry has been much maligned in recent years, it remains a vital part of the United States economy - especially that of the Northeast - and plays an increasing role in the nation's healthcare.The objective of the course is to provide you with an understanding of the industry and the role of the marketing department in the organization.
  • The focus will be on marketing to health care professionals and to patients, although the potential effect of other parties in product success will be briefly explored.
  • The economics of the industry will be highlighted.
  • To provide context, the regulatory framework of the industry and the "typical" organizational structure of a large pharmaceutical company will be discussed.
  • The effects of changes in the larger environment - changes in the media landscape and changes in the patient/physician relationship, to name two - will be investigated.
  • The numerous significant ethical issues facing the industry will be discussed. This course employs interactive discussion, guest speakers and a limited amount of lecture.
Economics of Healthcare / The Business of Health & Medical Care
This course is designed to give the student a general understanding of the economics of healthcare. More specifically, the course will allow students:
  • To understand what makes the Economics of Healthcare unique.
  • To understand Healthcare Markets: a) Demand b) Production and Costs c) Supply
  • To understand the market for Healthcare, Market Failure, and the Role of Government
  • Health Insurance, Third Party Payers, and Healthcare Financing.
  • Economic Evaluation in Healthcare: a) Equity, Efficiency, Ethics b) Cost-Benefit c) Measuring Value and Outcomes
Economic Transformation of Healthcare
This course is designed to give the student a general understanding of applied economics of healthcare. It provides an advanced critical analysis of the delivery of healthcare services and how it is constantly changing. It evaluates the responses of major players including hospitals, physicians, payers, life sciences and new entrants to the market. As expectations for a unified, efficient, cost effective, and high quality global system continue to be desired, the entire ecosystem is trying to adapt. At the end of the course, students will understand why economics in Healthcare is constantly changing and the major drivers impacting the system. While this course is an economics course, it is focused on the application of principles in real life settings and uses current events to highlight their impact. We also try and touch upon regulatory reform and understand how each constituent has an impact on the others within the system. In order to bring in other perspectives, c-suite level executives are brought in as guests.

Economics of the Pharmaceutical and Biotechnology Industries
This course offers the student an overview of the management, economics, and policy issues that drive and challenge the pharmaceutical and biotechnology industries. Included also in the biotechnology heading will be the multidisciplinary medical device industry. The focus of this course is to give the student insight into these important health care industries and their business transformation in an environment of health care reform. The objectives of the course will include: an understanding of the cost structure of these important market sectors; a focus on the management and economics of the powerful R&D process and its relationship to an ever changing technological environment and innovation dominance; the explosive growth of the biologic and genomics markets; and the interconnectivity of the pharmaceutical and biotechnology industries. Discussion will also include the role of government regulation on these industries. The course will highlight the role of these industries in a global marketplace.

Biotechnology Industry, Structure, and Strategy
Biotechnology started as a science, referring to the use of living cells as factories to produce protein through manipulation of genes. Yet today, biotechnology refers to an industry, with the top companies in the sector exceeding some of the major pharmaceutical companies in market capitalization. No longer are biotechnology companies constrained to using recombinant DNA technology alone, as the moniker is assigned today to any small company engaged in any life sciences-related research directed toward developing a commercial product, using any scientific means. Belonging to the sector usually also implies a culture – small, nimble, visionary but practical, cash constrained but willing to risk it all. While some of the above characteristics are more idealized than real, it is certainly the case that, while the key factors for success in a development stage company include the very same scientific, analytic, and/or managerial talents that reside in “big pharma”, the context is different, requiring the organization to incorporate some additional skills to ensure survival, and non-traditional systems to support success
  • The foundation of this course will be the core curriculum that you have all mastered during your first year at Stern. You will be at an advantage, in that regard, relative to some of your future colleagues who work in the industry today.
  • The long product development cycles inherent to the industry may minimize the rigor behind decision-making, since there is a long time lag between the action taken, and its ultimate impact.
  • Moreover, paradoxically, there is a “comfort” to operating at a significant loss for many years, spending hundreds of millions of dollars of investors’ money, relieving the incentive to generate incremental revenue or savings that seem insignificant relative to the scale of the investment and the size of the opportunity.
  • Finally, the need to constantly raise money sometimes favors promotion over analysis, and short-term impact on share price, rather than long-term creation of value.